Literature DB >> 25060604

Verapamil decreases the glucose-lowering effect of metformin in healthy volunteers.

Sung Kweon Cho1, Choon Ok Kim, Eun Seok Park, Jae-Yong Chung.   

Abstract

AIM: The organic cation transporter 1 (OCT1) plays a key role in the cellular transport of metformin and its subsequent glucose-lowering effect. A recent non-clinical study reported that metformin uptake into hepatocytes is regulated via OCT1, and that uptake was strongly inhibited by verapamil. Therefore, we investigated the effects of verapamil co-administration on the pharmacokinetics and pharmacodynamics of metformin in humans.
METHODS: We evaluated the pharmacokinetics and the anti-hyperglycaemic effects of metformin using an oral glucose tolerance test (OGTT) in 12 healthy participants, before (day 1) and after metformin treatment (day 2), and again on days 15 and 16 after co-administration with verapamil.
RESULTS: Verapamil inhibited the ability of metformin to reduce maximum blood glucose concentrations (ΔGmax ) by 62.5% (P = 0.008) and decreased the area under the glucose concentration-time curve (ΔAUCgluc ) by 238% (P = 0.015). However, verapamil did not significantly alter the Cmax and the AUC of metformin, nor its renal clearance.
CONCLUSIONS: Our results suggest that verapamil remarkably decreases the glucose-lowering effect of metformin, possibly by acting as a competitive inhibitor of OCT1.
© 2014 The British Pharmacological Society.

Entities:  

Keywords:  OCT1; drug interaction; metformin; verapamil

Mesh:

Substances:

Year:  2014        PMID: 25060604      PMCID: PMC4256631          DOI: 10.1111/bcp.12476

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  30 in total

1.  Interaction of organic cations with a newly identified plasma membrane monoamine transporter.

Authors:  Karen Engel; Joanne Wang
Journal:  Mol Pharmacol       Date:  2005-08-11       Impact factor: 4.436

2.  Metformin kinetics in healthy subjects and in patients with diabetes mellitus.

Authors:  G T Tucker; C Casey; P J Phillips; H Connor; J D Ward; H F Woods
Journal:  Br J Clin Pharmacol       Date:  1981-08       Impact factor: 4.335

Review 3.  Verapamil: a review of its pharmacological properties and therapeutic use in coronary artery disease.

Authors:  R N Brogden; P Benfield
Journal:  Drugs       Date:  1996-05       Impact factor: 9.546

4.  Naringin is a major and selective clinical inhibitor of organic anion-transporting polypeptide 1A2 (OATP1A2) in grapefruit juice.

Authors:  D G Bailey; G K Dresser; B F Leake; R B Kim
Journal:  Clin Pharmacol Ther       Date:  2007-02-14       Impact factor: 6.875

5.  Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with Type 2 diabetes in UK primary care.

Authors:  M N Cook; C J Girman; P P Stein; C M Alexander
Journal:  Diabet Med       Date:  2007-02-28       Impact factor: 4.359

6.  Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action.

Authors:  Yan Shu; Steven A Sheardown; Chaline Brown; Ryan P Owen; Shuzhong Zhang; Richard A Castro; Alexandra G Ianculescu; Lin Yue; Joan C Lo; Esteban G Burchard; Claire M Brett; Kathleen M Giacomini
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

7.  Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin.

Authors:  De-Sheng Wang; Johan W Jonker; Yukio Kato; Hiroyuki Kusuhara; Alfred H Schinkel; Yuichi Sugiyama
Journal:  J Pharmacol Exp Ther       Date:  2002-08       Impact factor: 4.030

Review 8.  Metformin: an update.

Authors:  Dmitri Kirpichnikov; Samy I McFarlane; James R Sowers
Journal:  Ann Intern Med       Date:  2002-07-02       Impact factor: 25.391

9.  Identification of cysteines in rat organic cation transporters rOCT1 (C322, C451) and rOCT2 (C451) critical for transport activity and substrate affinity.

Authors:  Alexander Sturm; Valentin Gorboulev; Dmitry Gorbunov; Thorsten Keller; Christopher Volk; Bernhard M Schmitt; Peter Schlachtbauer; Giuliano Ciarimboli; Hermann Koepsell
Journal:  Am J Physiol Renal Physiol       Date:  2007-06-13

10.  Relationship between hepatic glucose production and fasting plasma glucose concentration in patients with NIDDM.

Authors:  C Y Jeng; W H Sheu; M M Fuh; Y D Chen; G M Reaven
Journal:  Diabetes       Date:  1994-12       Impact factor: 9.461

View more
  19 in total

Review 1.  Key Pharmacokinetic Essentials of Fixed-Dosed Combination Products: Case Studies and Perspectives.

Authors:  Ranjeet Prasad Dash; Rana Rais; Nuggehally R Srinivas
Journal:  Clin Pharmacokinet       Date:  2018-04       Impact factor: 6.447

Review 2.  Transporters in Drug Development: 2018 ITC Recommendations for Transporters of Emerging Clinical Importance.

Authors:  Maciej J Zamek-Gliszczynski; Mitchell E Taub; Paresh P Chothe; Xiaoyan Chu; Kathleen M Giacomini; Richard B Kim; Adrian S Ray; Sophie L Stocker; Jashvant D Unadkat; Matthias B Wittwer; Cindy Xia; Sook-Wah Yee; Lei Zhang; Yan Zhang
Journal:  Clin Pharmacol Ther       Date:  2018-08-08       Impact factor: 6.875

3.  Ligand-dependent modulation of hOCT1 transport reveals discrete ligand binding sites within the substrate translocation channel.

Authors:  Kelli H Boxberger; Bruno Hagenbuch; Jed N Lampe
Journal:  Biochem Pharmacol       Date:  2018-08-20       Impact factor: 5.858

Review 4.  A Comprehensive Review of Drug-Drug Interactions with Metformin.

Authors:  Tore Bjerregaard Stage; Kim Brøsen; Mette Marie Hougaard Christensen
Journal:  Clin Pharmacokinet       Date:  2015-08       Impact factor: 6.447

5.  Moxifloxacin Is a Potent In Vitro Inhibitor of OCT- and MATE-Mediated Transport of Metformin and Ethambutol.

Authors:  Lindsey H M Te Brake; Jeroen J M W van den Heuvel; Aaron O Buaben; Reinout van Crevel; Albert Bilos; Frans G Russel; Rob E Aarnoutse; Jan B Koenderink
Journal:  Antimicrob Agents Chemother       Date:  2016-11-21       Impact factor: 5.191

6.  Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers.

Authors:  Elise J Smolders; Angela Colbers; Clara T M M de Kanter; Kirsten Velthoven-Graafland; Leonie T Wolberink; Noor van Ewijk-Beneken Kolmer; Joost P H Drenth; Rob E Aarnoutse; Cees J Tack; David M Burger
Journal:  Br J Clin Pharmacol       Date:  2017-06-06       Impact factor: 4.335

7.  Comparison of Hepatic Transporter Tissue Expression in Rodents and Interspecies Hepatic OCT1 Activity.

Authors:  Bridget L Morse; John K Fallon; Anil Kolur; Andrew T Hogan; Philip C Smith; Kathleen M Hillgren
Journal:  AAPS J       Date:  2021-04-26       Impact factor: 4.009

8.  Differential effects of metformin-mediated BSEP repression on pravastatin and bile acid pharmacokinetics in humans: A randomized controlled trial.

Authors:  Melissa Metry; Samuel A Krug; Vijaya Kumari Karra; Maureen A Kane; Jeffrey C Fink; Yan Shu; Hongbing Wang; James E Polli
Journal:  Clin Transl Sci       Date:  2022-08-07       Impact factor: 4.438

Review 9.  Contribution of Humanized Liver Chimeric Mice to the Study of Human Hepatic Drug Transporters: State of the Art and Perspectives.

Authors:  Anna Zerdoug; Marc Le Vée; Shotaro Uehara; Béatrice Lopez; Christophe Chesné; Hiroshi Suemizu; Olivier Fardel
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2022-07-06       Impact factor: 2.569

10.  A Whole-Body Physiologically Based Pharmacokinetic Model Characterizing Interplay of OCTs and MATEs in Intestine, Liver and Kidney to Predict Drug-Drug Interactions of Metformin with Perpetrators.

Authors:  Yiting Yang; Zexin Zhang; Ping Li; Weimin Kong; Xiaodong Liu; Li Liu
Journal:  Pharmaceutics       Date:  2021-05-11       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.